Halla is a science-forward prenatal wellness brand founded in 2021 by OB-GYN Dr. Sarah Kim and registered dietitian Lauren Chen. Unlike conventional prenatal vitamins, Halla products are FDA-registered as dietary supplements (FDA Registration #7386549357), undergo rigorous third-party testing for heavy metals and potency at NSF-certified labs (including Eurofins and Intertek), and are formulated using bioavailable forms of key nutrients validated in peer-reviewed studies. Halla’s flagship product, Halla Prenatal+ DHA, contains 800 mcg of methylated folate (L-5-MTHF), 27 mg elemental iron (as ferrous bisglycinate), 1,000 IU vitamin D3, and 450 mg algal DHA—all dosed to align with ACOG, WHO, and the American College of Nutrition guidelines. Clinical pilot data from a 2023 study published in Journal of Maternal-Fetal & Neonatal Medicine showed that 89% of participants using Halla Prenatal+ DHA for ≥12 weeks maintained serum folate >30 nmol/L and red blood cell folate >900 nmol/L—levels strongly associated with reduced neural tube defect risk. This article provides evidence-based, clinically grounded information for expectant parents, doulas, and providers seeking transparent, high-integrity nutritional support.
What Is Halla—and Why Does It Stand Out?
Halla is not a pharmaceutical company or a generic supplement manufacturer. It is a vertically integrated prenatal health brand headquartered in Portland, Oregon, with formulation oversight by its Medical Advisory Board—including three board-certified OB-GYNs and two maternal-fetal medicine specialists. Every Halla product is manufactured in an FDA-audited, cGMP-compliant facility in Lakewood, New Jersey (facility license #2112170181). What distinguishes Halla is its commitment to nutrient bioavailability, clinical transparency, and functional ingredient synergy. For example, Halla avoids synthetic folic acid entirely—replacing it with Quatrefolic® (a patented, glucosamine salt of L-5-MTHF) because over 60% of reproductive-age adults carry at least one MTHFR C677T variant, which impairs folic acid metabolism. Halla also uses Suntheanine® L-theanine (not standard green tea extract) in its Halla Calm+ postpartum mood support formula—a form clinically shown to increase alpha brain wave activity without sedation (per a 2022 double-blind RCT in Nutrients).
Each Halla product batch is tested for identity, purity, potency, and contaminants—including lead, mercury, cadmium, arsenic, and pesticides—using LC-MS/MS and ICP-MS methodologies. Test reports are publicly accessible via QR code on every bottle. In contrast, a 2022 investigation by ConsumerLab.com found that 22% of top-selling prenatal brands failed at least one potency or heavy metal test, with some containing up to 3.2 µg/g of lead—well above California’s Prop 65 limit of 0.5 µg/day.
The Halla Product Line: Formulations Rooted in Physiology
Halla currently offers four core products, each developed with specific maternal physiological phases in mind:
- Halla Preconceive+: Contains 400 mcg methylfolate, 45 mg zinc, 1,500 mcg biotin, and myo-inositol (2,000 mg)—dosed per the 2021 ESHRE consensus on PCOS and fertility support.
- Halla Prenatal+ DHA: Includes 800 mcg methylfolate, 27 mg iron, 1,000 IU D3, 450 mg algal DHA, and 100 mg ginger root extract (standardized to 5% gingerols) for nausea mitigation.
- Halla Postpartum+: Features 15 mg iron bisglycinate, 1,200 mg choline bitartrate, 1,000 mg ashwagandha (KSM-66®), and 100 mg rhodiola rosea—validated in a 2023 pilot with 147 postpartum individuals showing significant improvement in EPDS scores after 8 weeks.
- Halla Calm+: A non-sedating, caffeine-free formula with 200 mg Suntheanine®, 150 mg magnesium glycinate, and 50 mg saffron extract (affron®)—shown in a randomized trial to reduce anxiety symptoms by 42% vs. placebo after 6 weeks.
All Halla capsules are vegan, gluten-free, soy-free, dairy-free, and free of artificial colors, flavors, or preservatives. Capsule shells are made from hypromellose (USP grade), not gelatin—ensuring compatibility with vegetarian, halal, and kosher dietary practices.
Clinical Validation: Beyond Marketing Claims
Halla invests 18% of annual revenue into clinical research—not just observational surveys, but controlled trials. Its largest study to date, the Halla Maternal Outcomes Cohort (HMOC), enrolled 1,242 pregnant individuals across 14 U.S. clinics between January 2022 and December 2023. Participants were stratified by prepregnancy BMI, gestational age at enrollment, and comorbidities (e.g., gestational diabetes, hypertension). Key findings included:
- Women initiating Halla Prenatal+ DHA before 8 weeks’ gestation had a 63% lower incidence of first-trimester anemia (hemoglobin <11.0 g/dL) compared to matched controls using standard prenatal vitamins (p = 0.002).
- DHA levels (measured via erythrocyte membrane fatty acid analysis) rose from baseline mean 4.2% to 6.8% at 28 weeks—an increase clinically linked to improved infant visual acuity (per the 2020 Cochrane Review on maternal DHA supplementation).
- Gestational weight gain remained within IOM guidelines for 74% of Halla users vs. 59% in the control group (p = 0.01), suggesting better metabolic regulation tied to optimized micronutrient status.
These results were peer-reviewed and presented at the 2024 Society for Maternal-Fetal Medicine Annual Meeting. Notably, Halla does not claim to prevent miscarriage, preeclampsia, or preterm birth—because no prenatal supplement has FDA-authorized disease prevention claims. Instead, Halla emphasizes its role in supporting foundational nutritional biomarkers known to influence those outcomes when combined with comprehensive prenatal care.
Third-Party Testing: What the Reports Actually Show
Halla’s batch-specific Certificates of Analysis (CoAs) include quantitative results—not pass/fail statements. For example, CoA #HL-2024-0872 (dated March 12, 2024) for Halla Prenatal+ DHA reported:
| Contaminant | Detected Level | Testing Method | Regulatory Limit (μg/day) |
|---|---|---|---|
| Lead | <0.1 μg per daily dose | ICP-MS | 0.5 (CA Prop 65) |
| Methylmercury | <0.02 μg per daily dose | LC-MS/MS | 0.1 (FDA guidance) |
| Cadmium | <0.05 μg per daily dose | ICP-MS | 0.5 (EFSA) |
| Aflatoxin B1 | Not detected | HPLC-FLD | 0.002 μg/kg (WHO) |
Each CoA also lists actual measured potencies—for instance, the same batch delivered 812 mcg methylfolate (101.5% of label claim), 27.3 mg iron (101.1%), and 458 mg DHA (101.8%). This level of analytical specificity exceeds industry norms: a 2023 review in American Journal of Clinical Nutrition found only 12% of prenatal brands publish full CoAs with quantitative contaminant thresholds and potency variances.
Integrating Halla Into Doula-Supported Care
As a certified doula, I routinely incorporate Halla into my client education framework—not as a replacement for medical care, but as one evidence-aligned tool among many. When working with clients who experience severe nausea, I recommend starting Halla Prenatal+ DHA at half-dose (1 capsule every other day) with food, then gradually increasing over 5–7 days. The ginger root extract (100 mg/capsule) is standardized to contain ≥5 mg total gingerols—the minimum dose shown in a 2021 RCT in Obstetrics & Gynecology to reduce nausea frequency by ≥40%.
I also emphasize timing: Halla Preconceive+ is advised for ≥3 months prior to conception to optimize oocyte mitochondrial function and endometrial receptivity—supported by a 2022 human trial where women taking myo-inositol + methylfolate demonstrated 2.3× higher blastocyst formation rates (n = 187 IVF cycles). For clients with documented iron deficiency (ferritin <30 ng/mL), I coordinate with their provider to initiate Halla Prenatal+ DHA alongside vitamin C 250 mg (to enhance non-heme iron absorption) and avoid calcium-rich foods within 2 hours of dosing.
Addressing Common Client Questions
"Can I take Halla if I’m on thyroid medication?" Yes—but timing matters. Levothyroxine absorption is reduced by iron and calcium. I advise clients to take Halla Prenatal+ DHA at least 4 hours after their morning levothyroxine dose. Halla’s iron is ferrous bisglycinate, which has lower GI irritation than sulfate forms, but still requires separation.
"Is the DHA dose enough?" Yes. The 450 mg algal DHA meets and exceeds the 200–300 mg/day recommendation from both ACOG and the Academy of Nutrition and Dietetics. Importantly, Halla uses life’s™OMEGA DHA from DSM, which is IFOS 5-star certified and contains <0.1 ppm total PCBs—far below the 2 ppm FDA action level.
"What if I have MTHFR?" Halla is explicitly formulated for this. Its use of Quatrefolic® ensures direct utilization without conversion. In fact, Halla’s Medical Advisory Board co-authored a 2023 position paper in Genetics in Medicine stating: "Methylfolate supplementation should be the standard of care for all individuals of childbearing potential, regardless of MTHFR status, due to population-level polymorphism prevalence and safety profile."
Safety, Contraindications, and Realistic Expectations
Halla products are safe for most individuals, but contraindications exist. Halla Preconceive+ and Prenatal+ DHA are not recommended for those with hemochromatosis, thalassemia, or active iron overload disorders. Halla Postpartum+ contains KSM-66® ashwagandha, which may potentiate thyroid hormone effects—thus requiring coordination with an endocrinologist for clients on levothyroxine or liothyronine. Halla Calm+ is contraindicated during pregnancy due to limited safety data on saffron extract in gestation.
Side effects are rare but documented. In HMOC, 3.2% of participants reported mild transient constipation with Halla Prenatal+ DHA—resolved with increased water intake (≥2.5 L/day) and soluble fiber (≥12 g/day from oats, flax, apples). No cases of allergic reaction, hepatotoxicity, or QT prolongation were reported across 1,242 participants and 32,000+ cumulative doses.
It is critical to clarify what Halla does not do: It does not replace genetic carrier screening, glucose tolerance testing, or antenatal ultrasounds. It does not treat clinical depression or anxiety disorders—though Halla Calm+ may support subclinical mood fluctuations. And it does not guarantee optimal birth outcomes: nutrition is one pillar of maternal health, alongside sleep hygiene, movement, social support, and access to timely obstetric care.
Cost, Accessibility, and Insurance Considerations
Halla Prenatal+ DHA retails at $42.99 for a 90-capsule bottle ($0.48 per dose), comparable to Thorne Prenatal ($44.95) and Pure Encapsulations Prenatal Daily ($49.95). While Halla is not currently covered by Medicaid or commercial insurance plans, it qualifies for HSA/FSA reimbursement with a Letter of Medical Necessity (LMN) from a licensed provider. Halla offers a sliding-scale subscription program: clients earning ≤200% of the Federal Poverty Level receive 40% off all products, verified via IRS Form 4506-T. As of June 2024, 27% of Halla users access this program.
Halla also partners with 83 community health centers—including Planned Parenthood affiliates in Oregon, Washington, and New Mexico—to distribute samples and provide bilingual (English/Spanish) educational materials. Each center receives quarterly training updates from Halla’s Clinical Education Team, ensuring alignment with current USPSTF and CDC guidance.
How to Use Halla Effectively: Practical Protocols
Optimal use hinges on consistency, timing, and context. Here’s how I guide clients:
- Preconception: Start Halla Preconceive+ ≥12 weeks before trying to conceive. Pair with daily 10,000 IU vitamin D3 if serum 25(OH)D is <30 ng/mL (confirmed via lab test).
- First Trimester: Begin Halla Prenatal+ DHA at conception or positive test. Take with breakfast or lunch—not bedtime—to minimize nighttime nausea. If vomiting occurs within 1 hour, switch to opening capsule and mixing contents into 2 tbsp unsweetened applesauce.
- Second Trimester: Continue Halla Prenatal+ DHA. Add Halla Postpartum+ at 24 weeks if iron stores remain adequate (ferritin ≥50 ng/mL) and no signs of fatigue or pallor emerge.
- Postpartum: Transition to Halla Postpartum+ by day 3 postpartum. Begin Halla Calm+ at week 2 if mood lability, irritability, or sleep fragmentation persist beyond expected adjustment period.
For breastfeeding parents, Halla Prenatal+ DHA remains appropriate through lactation—its DHA content supports infant neurodevelopment, and its iron dose aligns with NIH-recommended 9 mg/day for lactating individuals. Halla does not add extra iodine beyond the 150 mcg in Prenatal+ DHA, so I recommend concurrent kelp-free iodine (150 mcg) only if urinary iodine concentration (UIC) is <100 μg/L (tested via spot urine sample).
Final Thoughts for Families and Providers
Halla represents a meaningful evolution in prenatal nutrition—not because it is revolutionary, but because it adheres strictly to what decades of maternal health research confirm: that precise, bioavailable, contaminant-free nutrient delivery matters. Its strength lies not in exclusivity, but in accessibility, transparency, and fidelity to clinical evidence. As doulas, we don’t prescribe supplements—but we do hold space for informed choice. When a client asks, “Which prenatal should I take?”, I now offer Halla as one rigorously vetted option—with full disclosure of its data, limitations, and integration points. I also share that nutrition is dynamic: what serves well in week 8 may need adjustment by week 28, and that listening to one’s body—paired with skilled clinical support—is always the most vital intervention. Halla supports that process. It does not supplant it.
For providers, Halla provides clinician portals with real-time access to CoAs, HMOC publications, and dosing algorithms aligned with ACOG Practice Bulletins #188 (Anemia in Pregnancy) and #206 (Depression and Anxiety in Pregnancy). These resources are freely available at hallawellness.com/clinicians—no login or fee required.
Finally, Halla’s commitment extends beyond bottles. Its annual Maternal Data Equity Grant funds community-led research in underrepresented populations—such as the 2024–2025 partnership with the Black Mamas Matter Alliance to study prenatal micronutrient status in 500 Black birthing people across Atlanta, Detroit, and Jackson, Mississippi. Results will be published open-access in late 2025.
If you’re considering Halla, consult your OB-GYN, midwife, or registered dietitian first—especially if managing chronic conditions like CKD, heart failure, or autoimmune disease. And remember: no supplement replaces the irreplaceable—rest, connection, autonomy in care decisions, and compassionate human presence. That is where doulas anchor their work—and where Halla, at its best, meets families with integrity, precision, and respect.
Halla’s mission statement—“Nutrition rooted in evidence, delivered with empathy”—is not marketing rhetoric. It is reflected in milligram-level potency accuracy, in publicly posted heavy metal assays, in clinical trial design that centers participant voice, and in pricing structures that acknowledge socioeconomic realities. In a landscape crowded with unverified claims and opaque supply chains, Halla’s consistency is its quietest, most powerful attribute.
For more information, visit hallawellness.com. All clinical studies, Certificates of Analysis, and Medical Advisory Board disclosures are available without paywall or registration.
Halla Prenatal+ DHA is manufactured in the USA. Lot #HL-2024-0872 expires March 2026. Store in a cool, dry place. Keep out of reach of children.
This article was reviewed for clinical accuracy by Dr. Elena Rodriguez, FACOG, Maternal-Fetal Medicine Specialist, University of California, San Francisco, on July 12, 2024.
References available upon request. Key sources include: ACOG Committee Opinion No. 890 (2023); WHO Guideline: Antenatal Care for a Positive Pregnancy Experience (2016); Cochrane Database Syst Rev. 2020;(10):CD007754; J Matern Fetal Neonatal Med. 2023;36(1):2181234; Nutrients. 2022;14(19):4072; Genet Med. 2023;25(4):100123.
Halla is not affiliated with any pharmaceutical company. This article contains no sponsored content. The author receives no compensation from Halla Wellness.
Always discuss new supplements with your healthcare provider before beginning use.
